$GOSS has been mentioned 7 times over the past 12 months by 2 FinTwit voices, with the first mention appearing on August 16, 2025. The most active voice discussing Gossamer Bio is @adamfeuerstein (Adam Feuerstein ✡️) with 3 mentions, followed by @microcapclub (MicroCapClub) with 4 mentions. The discussion has primarily focused on long research, with recent activity concentrated in late February 2026 around clinical trial data releases.

The most recent mentions center on Gossamer Bio's seralutinib study results in pulmonary arterial hypertension (PAH). @adamfeuerstein reported that the drug achieved only a 13-meter increase in six-minute walk distance versus placebo, which did not reach statistical significance. He also highlighted subgroup analysis concerns, noting that one-third of PAH patients showed a 5-meter difference, characterizing the overall data as "not good" despite the company's stated plans to pursue FDA approval.